Antineoplastic and immunomodulating agents | Tenderlake

Antineoplastic and immunomodulating agents

Contract Value:
-
Notice Type:
Contract Notice
Published Date:
13 July 2020
Closing Date:
07 August 2020
Location(s):
FRL04 Bouches-du-Rhône (FR FRANCE)
Description:
Supply of medicines Azacitidine, Bevacizumab, Erlotinib and Melphalan

Supply of medicines Azacitidine, Bevacizumab, Erlotinib and Melphalan.

Azacitidine injection

Azacitidine for injection.

Bevacizumab injection route - biosimilar medicine

Bevacizumab injection route - biosimilar medicine.

Bevacizumab injectable route - original drug for needs not covered by the biosimilar

Bevacizumab injectable route - original drug for needs not covered by the biosimilar.

Erlotinib oral

Erlotinib orally.

Melphalan injection

Melphalan injection.

Download full details as .pdf
The Buyer:
Centre hospitalier régional de Marseille
CPV Code(s):
33652000 - Antineoplastic and immunomodulating agents